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Background: Acquired thrombotic thrombocytopenic purpura (TTP) is an autoimmune disease in which anti-
ADAMTS13 autoantibodies cause severe enzyme deﬁciency. ADAMTS13 deﬁciency causes the loss of regulation of
von Willebrand factor multimeric size and platelet-tethering function, which results in the formation of
disseminatedmicrovascular plateletmicrothrombi. Precisely how anti-ADAMTS13 autoantibodies, or antibody sub-
sets, cause ADAMTS13 deﬁciency (ADAMTS13 activity generally b10%) has not been formally investigated.
Methods:We analysed 92 acquired TTP episodes at presentation, through treatment and remission/relapse using
epitope mapping and functional analyses to understand the pathogenic mechanisms of anti-ADAMTS13 IgG.
Results: 89/92 of TTP episodes had IgG recognising the ADAMTS13 N-terminal domains. The central spacer domain
was the only N-terminal antigenic target detected. 38/92 TTP episodes had autoantibodies recognising the N-
terminal domains alone; 54/92 TTP episodes also had antibodies against the ADAMTS13 C-terminal domains
(TSP2–8 and/or CUB domains). Changes in autoantibody speciﬁcity were detected in 9/16 patients at relapse, sug-
gesting a continued development of the disease. Functional analyses on IgG from 43 patients revealed inhibitory
IgGwere limited to anti-spacer domain antibodies. However, 15/43 patients had autoantibodies with no detectable
inhibitory action and asmany as 32/43 patients had autoantibodies with inhibitory function that was insufﬁcient to
account for the severe deﬁciency state, suggesting that in many patients there is an alternative pathogenic mecha-
nism.We therefore analysed plasma ADAMTS13 antigen levels in 91 acquired TTP presentation samples. We dem-
onstrated markedly reduced ADAMTS13 antigen levels in all presentation samples, median 6% normal (range 0–
47%), with 84/91 patients having b25% ADAMTS13 antigen. ADAMTS13 antigen in the lowest quartile at ﬁrst pre-
sentation was associated with increased mortality (odds ratio 5.7).
Conclusions: Anti-spacer domain autoantibodies are the major inhibitory antibodies in acquired TTP. However, de-
pletion of ADAMTS13 antigen (rather than enzyme inhibition) is a dominant pathogenic mechanism. ADAMTS13
antigen levels at presentation have prognostic signiﬁcance. Taken together, our results provide new insights into
the pathophysiology of acquired TTP.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-
threatening disorder associated with inherited or, more commonly,
acquired deﬁciency in the plasma metalloprotease, ADAMTS13 (Levy
et al., 2001; Fujikawa et al., 2001). Severe ADAMTS13 deﬁciency (activity
generally b10%) results in insufﬁcient processing of von Willebrand fac-
tor (VWF)— a criticalmediator of normal platelet tethering. ADAMTS13grant (FS/10/13/28073).
UCL, 51 Chenies Mews, London
.
. This is an open access article underdeﬁciency results in the accumulation of the most haemostatically active
“ultra-large” forms of VWF in plasma. These UL-VWF multimers can un-
ravel during passage through themicrocirculation,which precipitates un-
wanted platelet aggregation and multi-organ microvascular thrombosis.
This accounts for the clinical sequelae of TTP, namely thrombocytopenia
and microangiopathic haemolytic anaemia, variably with neurological,
cardiac, gastro-intestinal and/or renal involvement.
Autoantibodies against ADAMTS13, predominantly immunoglobulin
class G (IgG), are present in the majority of acquired TTP patients and
cause profound loss of VWF-cleaving function (Hovinga et al., 2010;
Ferrari et al., 2007, 2009; Peyvandi et al., 2008). Antibodies that bind the
N-terminal domains of ADAMTS13 (herein termed MDTCS) are detected
inmost patients, although antibodies recognising the C-terminal domains
of ADAMTS13 have also been reported (Klaus et al., 2004; Luken et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ever, epitope mapping studies alone do not identify the antibodies that
are inhibitory and/or pathogenic. For example, non-inhibitory IgG anti-
bodies that do not impair ADAMTS13 function in vitro may still be path-
ogenic and compromise VWF processing in vivo (Scheiﬂinger et al.,
2003). Autoantibodies against different ADAMTS13 domains likely inhibit
enzyme function to different extents, andmay cause deﬁciency in vivo via
distinct mechanisms.
Treatment of acquired TTP involves plasma exchange (PEX) to pro-
vide a new source of ADAMTS13. Steroids are used to target the autoim-
mune component of the disease. Therapy with rituximab reduces rates
of recurrence (Scully et al., 2011; Westwood et al., 2013). Recombinant
ADAMTS13 is currently undergoing trials for the treatment of inherited
TTP. However, its effectiveness in the more prevalent acquired form of
the disease (~95% cases), with inhibitory anti-ADAMTS 13 IgG antibod-
ies, is unknown.
In this study, we characterised the repertoire of antibodies in pa-
tients with acute idiopathic TTP at presentation and, for the ﬁrst time,
through therapy, remission and relapse, and explored the inhibitory po-
tential and other pathogenic mechanisms of these antibodies. Identiﬁ-
cation of the pathogenic mechanisms that cause loss of ADAMTS13
activity is critical to our understanding of acquired TTP, aswell as poten-
tially for monitoring and treating acquired TTP patients in the future.
2. Methods
2.1. Patients
Citrated plasma samples from a non-sequential cohort of 78 patients
with acquired idiopathic TTP referred to our reference centre between
2000 and 2012 were analysed. Presenting samples from 92 acute epi-
sodes of TTP were included in the domain-speciﬁcity study, of which
43 subsequently underwent IgG extraction for functional analysis. A
ﬂowchart of sample distribution of the 92 acute episodes is shown in
Fig. 1.Fig. 1. Flowchart of the 92TTP patients were diagnosed clinically based on the combination of
microangiopathic haemolytic anaemia with thrombocytopenia and
end-organ damage with no other known cause (Scully et al., 2012). Pa-
tients with other thrombotic microangiopathies, or TTP secondary to
HIV or pregnancy were excluded. All presentation samples were taken
before plasma exchange or rituximab were commenced. All patients
had severe deﬁciency in plasma ADAMTS13 activity (b10%), with the
exception of one patient with 12% activity, and one with 27% activity
(although this sample was taken after plasma infusion had been
given) and were positive for anti-ADAMTS13 IgG (Gerritsen et al.,
1999; Yarranton et al., 2004; Kokame et al., 2005; Scully et al., 2007).
Patients were selected based on their medium/high anti-ADAMTS13
titre (i.e. N15% using a well-established in-house anti-ADAMTS13 IgG
ELISA (Scully et al., 2007)). Through exclusion of patients with low-
titre anti-ADAMTS13 antibodies, this cohort of patients was conse-
quently enriched for those that relapsed patients and/or died during a
TTP episode, facilitating analysis of the longitudinal humoral response
and disease severity. For the purpose of the study, relapse was deﬁned
as either clinical relapse, or acute drop in plasma ADAMTS13 activity
(to b10%) during follow-up, despite normal routine laboratory parame-
ters, necessitating treatment with elective rituximab. Follow-up ended
on May 14th 2014.
Citrated plasma samples were also collected from 67 normal healthy
adult volunteers for use as controls. The research was approved by the
Research Ethics Committee (08/H0810/54, 08/H0810/54, 08/H0716/
72). Informed consent was obtained from all patients and healthy
volunteers. Assent was obtained from the patient representatives for
those TTP patients that lacked capacity to give informed consent.
2.2. Expression and Puriﬁcation of ADAMTS13 and VWF Fragments
Full-length ADAMTS13 and fragments; metalloprotease to
disintegrin-like domain (MD), metalloprotease to cysteine-rich do-
main (MDTC), metalloprotease to spacer domain (MDTCS), TSP2–8
domains and CUB1/2 domains were expressed in HEK293 cells andacute TTP episodes.
Fig. 2. Domain organisation of ADAMTS13 and domain speciﬁcity of anti-ADAMTS13 antibodies at TTP presentation. A) Domain organisation of ADAMTS13 consisting of the
metalloprotease domain (MP), disintegrin-like domain (Dis), eight thrombospondin repeats (1–8, green), Cysteine-rich domain (Cys), spacer domain and two C-terminal CUB domains.
Underneath are denoted the domain fragments used in this study— theN-terminal domain fragments, MDTCS,MDTC andMD, and the C-terminal TSP2–8. B) Graph depicting summary of
anti-ADAMTS13 domain speciﬁcity ELISAs for 92 TTP patient episodes. TTP patient plasmas (diluted 1/50) were analysed for IgG that recognised immobilised full length ADAMTS13 both
with andwithout preincubation of plasmaswith 10 nMMDTCS. For each patient, the proportion of full length ADAMTS13 binding thatMDTCS could not compete for is plotted in grey (left
axis; proportion non-MDTCS Abs, %). Plasma samples were also analysed for the presence of anti-TSP2–8 IgG in a separate ELISA plotted in black (right axis: TSP2–8, mAU). All patients
were positive for anti-N-terminal antibodies, except samples labelled with *, denoting the three patients in which MDTCS could not compete at all for full-length ADAMTS13 binding. Pa-
tients 1–38 are termed anti-N-terminal alone, asMDTCS competed for N85% (dotted line) full length ADAMTS13 binding and these samples exhibited noor very low recognition of TSP2–8.
Patients 39–64 are positive for anti-TSP2–8 antibodies. Patients 65–92 are termed anti-CUB, as MDTCS competed for b85% (dotted line) of full length ADAMTS13 binding, consistent with
the presence of anti-C-terminal antibodies, but these samples exhibited no or very low recognition of TSP2–8.
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were expressed and puriﬁed as previously described (Supplementary
Methods) (Pos et al., 2010).
2.3. Domain Speciﬁcity of Anti-ADAMTS13 Antibodies in TTP Patient
Plasmas
Maxisorb plates (Nunc) were coated with 2.5 μg/ml puriﬁed
ADAMTS13, MDTCS or TSP2–8 in 50 mM sodium carbonate buffer
pH 9.6 and blocked with PBS/2.5% BSA/1% fetal calf serum (FCS) for
2 h. TTP patient, or pooled control plasma were diluted 1/20 to 1/50 in
PBS/1% BSA/1% FCS and incubated in duplicate with wells for 1 h.
Wells were washed and bound anti-ADAMTS13 antibodies detected
with anti-human IgG-HRP (Dako). OPD (Sigma) was used for colour
development. In parallel, identical experiments were set up, except
that the diluted plasma samples were preincubated with either 20 nM
MD, 20 nM MDTC or 10 nM MDTCS for 30 min, before applying to
wells coated with full-length ADAMTS13. The ability of these fragments
to compete for autoantibody binding to immobilised ADAMTS13 was
assessed by comparison to samples that were preincubated without
an ADAMTS13 fragment.
Based on the results of these assays, patients were divided into
categories:
Anti-N-terminal autoantibodies alone MDTCS competed for N85% of
full-length ADAMTS13 binding, and patients ex-
hibited no speciﬁc immunoreactivity with
TSP2–8 domains in a separate ELISA.Anti-TSP2–8 autoAb immunoreactivity with TSP2–8 domains.Anti-CUB1/2 autoAb MDTCS competed for b85% of full-length
ADAMTS13 binding and patient plasma exhib-
ited no speciﬁc immunoreactivity with TSP2–8
domains by ELISA.2.4. IgG Extraction
Total IgG was isolated from TTP patient and healthy control
plasmas using Melon™ gel spin columns according to
manufacturer's instructions (Thermo Scientiﬁc). IgG was dialysed
into 20 mM Tris, pH 7.6 150 mM NaCl and quantiﬁed using an IgG
ELISA (Bethyl Laboratories).2.5. Antibody-Mediated Inhibition of ADAMTS13 Proteolysis of VWF115
and VWF106
The ability of isolated total IgG from TTP patients to inhibit
ADAMTS13 function was assessed using VWF115 and VWF106 (Pos
et al., 2010). Brieﬂy, 2 nM ADAMTS13 (ﬁnal concentration) in
20 mM Tris pH 7.6, 150 mM NaCl was preincubated for 1 h with
5 mM CaCl2 both with and without 17 μM total IgG isolated from
TTP or control plasmas. 5 μMVWF115was added to start the reaction
and incubated at 37 °C. At 0 to 60 min, subsamples were stopped and
proteolysis monitored by SDS-PAGE and Coomassie staining. For
analysis of VWF106 proteolysis, similar reactions were set up, using
3.5 nM ADAMTS13, 29 μM total IgG, and reaction times extended to
2 h.
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and Competition With MDTC
MDTCS (0.125 nM; ﬁnal concentration) in 5 mM Bis Tris, 25 mM
CaCl2, 0.005% Tween, pH 6.0 was preincubated at 37 °C for 30 min with
0–5.6 μM total IgG isolated from TTP or healthy plasmas. 1 μM FRETS-
VWF73 substrate (Peptide International) was added and ﬂuorescence
measured for 1 h to monitor substrate proteolysis. After titration of
each IgG preparation, assays were repeated at three different IgG
concentrations spanning the IC50 for each sample. This was per-
formed with and without preincubation with 10 nM puriﬁed MDTC,
to ascertain the proportion of inhibition attributable to anti-spacer do-
main antibodies.
2.7. ADAMTS13 ELISA
ADAMTS13 concentrations in healthy control and TTP patient plas-
ma samples were quantiﬁed by ELISA using a rabbit anti-ADAMTS13
antibody (anti-TSP2–4 depleted) for capture, and biotinylated anti-
TSP2–4 polyclonal antibody and streptavidin-conjugated peroxidase
for detection, as previously described (Chion et al., 2007; Andersson
et al., 2012). Plasmas were diluted from 1/25 to 1/200 in PBS 1% BSA,
each analysed in duplicate. To test whether anti-ADAMTS13 autoanti-
bodies interferewith the ELISA, 2 μl pooled normal plasmawas preincu-
bated with and without 4 μl of isolated IgG from 14 different TTP
patients prior to incubation with wells.
2.8. Statistical Analyses
Statistical analyses were performed using SPSS and GraphPad Prism
software. For continuous variables, differences between patients with
varying patterns of domain speciﬁcity were evaluated by the Mann
Whitney U test or the Kruskal Wallis test. For discrete variables, differ-
ences were evaluated using the χ2 test or Fisher's exact test. Cumulative
incidence and Gray's test were used to compare the incidence of relapse
between groups. Logistic regression analysis was applied to compute
odds ratios (ORs) and 95% conﬁdence intervals (CIs), which were used
as an estimate of the likelihood of mortality. A probability (p) value of
b0.05 was deemed statistically signiﬁcant.
3. Results
3.1. Patient Characteristics
The clinical and laboratory characteristics of the 92 TTP episodes in
78 non-consecutive patients are summarised in Table 1. Further clinical
and biochemical characteristics of this group are available in the Supple-
mentary Results.
3.2. Domain Speciﬁcity of TTP Autoantibodies at Presentation
To examine the domain speciﬁcity of anti-ADAMTS13 autoanti-
bodies in TTP patients at presentation, we developed ELISA-based and
competition ELISA assays. All TTP patient plasmas (diluted 1/50)
contained IgG that strongly recognised immobilised full length
ADAMTS13 by ELISA (Supplementary Fig. 1). The ADAMTS13
N-terminal domains (MDTCS — see Fig. 2A) were poorly recognised
when immobilised onto wells, suggesting that direct coupling of
MDTCS appreciably compromises its immunoreactivity with TTP au-
toantibodies (data not shown). Therefore, we used a competition
assay in which TTP plasmas were preincubated with and without
10 nM MDTCS in solution (to preabsorb IgG recognising these
domains) prior to incubation with wells coated with full-length
ADAMTS13. This assay thus enabled estimation of the proportion of
anti-ADAMTS13 antibodies that recognised MDTCS, with the residu-
al binding detected representing IgG recognising the ADAMTS13 C-terminal domains (i.e. TSR2–8 and/or CUB1/2) (Supplementary
Fig. 1). Using this approach, 89/92 (97%) of TTP presentation samples
were designated to have immunoreactivity against the ADAMTS13
N-terminal domains (i.e. MDTCS competed for N5% of binding to
full-length ADAMTS13). Only in 3/92 patient samples (patients
#64, #91, #92) did MDTCS fail to compete for any full-length
ADAMTS13 binding, suggesting that these patients' IgG recognise
the ADAMTS13 C-terminal domains alone. These three patients
were amongst the patients with the lowest anti-ADAMTS13 titre in
this cohort.
We identiﬁed 38/92 (41%) patients (patients #1–38 in Fig. 2B) with
autoantibodies that recognised the ADAMTS13 N-terminal domains
alone, as MDTCS competed for N85% of full-length ADAMTS13 binding
(Fig. 2B) and they exhibited no speciﬁc immunoreactivity with
TSP2–8 domains in a separate ELISA (Supplementary Fig. 1). 26/92
(28%) patients had IgG recognising the ADAMTS13 TSR2–8 domains
(patients #39–64), of which 25/26 of these patients also had anti-
bodies recognising MDTCS. The remaining 28/92 (31%) patients
(patients #65–92) exhibited little/no immunoreactivity against
TSP2–8 domains, were, by elimination, determined to have an appre-
ciable proportion of their autoantibodies recognising the CUB1/2
domains. 26 of these 28 patients also had antibodies recognising
MDTCS. Patients could be assigned to different groups based on the
domain speciﬁcity (i.e. 38/92 “anti-N-terminal”, 51/92 “anti-N- and
anti-C-terminal” and 3/92 “anti-C-terminal”).
In 25 patients with a high proportion of antibodies recognising
MDTCS (total anti-ADAMTS13 IgG N40%, N80% anti-MDTCS), no evi-
dence of immunoreactivity against either MD or MDTC was detected
in separate competition ELISAs (Supplementary Fig. 2), strongly sug-
gesting that the spacer domain is the primary antigenic target amongst
those antibodies that recognise the N-terminal domains.
3.3. Domain Speciﬁcity, Patient Characteristics, Disease Severity
and Relapse
Therewas no difference in sex, ethnicity or anti-ADAMTS13 IgG titre
between the 38 patient samples assigned to the “anti-N-terminal”
group, and the 54 patient samples with anti-C-terminal antibodies (of
which 51 also had anti-N-terminal IgG). Analysis of the prognostic im-
plications of domain speciﬁcity of anti-ADAMTS13 was performed on
the62ﬁrst presentation samples. Domain speciﬁcity did not differ in pa-
tients who died (n= 16) from those who survived (n= 46). Therewas
also nodifference inmedianplatelet count, Hb or LDH, number of PEX to
remission, frequency of cardiac involvement or relapse rate between
patients with antibodies directed against C-terminal domains and
those with anti-N-terminal antibodies alone. This suggested to us that
the domain speciﬁcity, per se, of anti-ADAMTS13 autoantibodies was
not necessarily a major determinant of disease severity.
3.4. Identiﬁcation of Inhibitory Antibodies Against ADAMTS13
To explore the inhibitory potential of TTP patient autoantibodies, we
performed functional analyses using isolated total IgG (Fig. 3). Puriﬁed
total IgG (17 μM) from a TTP patient with high titre (105% by compari-
son to reference plasma (18, 20)) anti-ADAMTS13 IgG directed against
the N-terminal domains alone (#16 in Fig. 2B) appreciably inhibited
VWF115 proteolysis, although speciﬁc cleavage products were still de-
tected at this IgG concentration, suggesting that inhibitionwas not com-
plete under these conditions. Total IgG (17 μM) from another patient
(#81, remission sample) with similar anti-ADAMTS13 titre but only
anti-C-terminal antibodies, had no inhibitory effect upon VWF115 pro-
teolysis. Patient #61 at presentation (anti-ADAMTS13 IgG titre 99%)
with antibodies against both anti-N- and C-terminal domains partially
inhibited VWF115 cleavage at this IgG concentration.
VWF106, which is identical to VWF115 but lacks 9 residues from its
C-terminus critical to ADAMTS13 spacer domain binding, is proteolysed
Table 1
Summary table of acquired TTP patient characteristics, clinical features and test results.
Tabulation of the parameters for all cases, subsequently divided into ﬁrst episode and relapses, in a selected cohort based on high anti-ADAMTS 13 IgG antibody levels. Differences in clin-
ical and laboratory parameters are statistically presented. First presentation episodesweremore severe than relapse episodes as determined by increased frequency of neurological symp-
toms, lower Hb, higher LDH and increased number of PEX to achieve clinical remission.
TTP episodes
All (n = 92) First (n = 62) Relapse (n = 25) pa
Age, years (range) 43 (13–78) 44 (13–78) 40 (14–75) 0.38
Sex, n (%)
Female 64 (70%) 43 (69%) 18 (72%) 1.0
Ethnicity, n (%)
Caucasian 49 (53%) 37 (60%) 11 (44%) –
Afro-Caribbean 23 (25%) 14 (23%) 9 (36%) –
Asian 9 (10%) 5 (8%) 4 (16%) –
SE Asian 2 (2%) 2 (3%) 0 (0%) –
Mixed race 3 (3%) 2 (3%) 1 (4%) –
Unknown 6 (7%) 2 (3%) 0 (0%) –
Clinical features, n (%)
Neurology 65 (71%) 50 (81%) 15 (60%) b0.05
Cardiac 38 (41%) 28 (45%) 10 (40%) 0.63
Renal 34 (37%) 25 (40%) 9 (36%) 0.81
GI 29 (32%) 22 (35%) 7 (28%) 0.61
Fever 30 (33%) 25 (40%) 5 (20%) 0.08
Blood results (range)
Hb, g/dl 8.4 (3.6–13.8) 8.0 (3.6–11.8) 10.8 (4.8–13.8) b0.0005
Platelets, ×109/l 13 (3–89) 13 (3–60) 18 (3–89) 0.17
LDH, IU/l (NR 470–900 IU/l) 1569 (165–5000) 2046 (165–5000) 921 (276–3174) b0.005
ADAMTS13 assays (range)
ADAMTS13, % act (NR 55–126%) b5 (b5–27) b5 (b5–12) b5 (b5–27) –
Anti-ADAMTS13, % titre (NR b 6.1%) 58 (9–164) 65 (18–164) 34 (9–101) b0.0001
PEX to remission, pv (range) 16 (4–92) 21.5 (4–92) 12.25 (4–33) b0.005
Subsequent relapses
Number (%) 27 (29%) 12 (19%) 15 (60%) b0.005
Time to relapse, months (range) 19 (2–52) 28.5 (4–50) 16 (2–52) 0.24
Deaths (%) 21 (23%) 16 (26%) 3 (12%) 0.25
Follow-up, years (range) 5.6 (1.7–13.6)
Hb = haemoglobin, LDH= lactate dehydrogenase, NR = normal range, PV = plasma volumes.
a Comparison of ﬁrst presentation and relapses.
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3.5 nM ADAMTS13 and 2 hour reaction times, VWF106 was partially
proteolysed by ADAMTS13 after 120 min (Fig. 3). This cleavage was
minimally affected by isolated IgG from patient samples #61 and #16,
strongly suggesting that in both cases the inhibition observed in the
VWF115 assay is mediated by antibodies that recognise the spacer do-
main, and that any autoantibodies that recognise theMDTC domains ei-
ther do not impair ADAMTS13 function or are only present at very low
concentrations.Fig. 3. ADAMTS13 inhibition is mediated by anti-spacer antibodies. ADAMTS13 activity assays
samples. 2 nM ADAMTS13 proteolysed VWF115 into 10 kDa and 6.9 kDa fragments (−IgG),
7 μM rabbit polyclonal anti-ADAMTS13 led to complete inhibition. Identical reactions containi
#61 are shown (* denotes contaminating band from IgG extraction). In parallel, proteolysis o
was investigated using 3.5 nM ADAMTS13 and 2 hour reaction times. Under these conditions
was unaffected by normal IgG (NH IgG), but completely inhibited by rabbit polyclonal anti-AD
#81 and #61 are shown. TTP patient IgG does not inhibit proteolysis of VWF106.To examine further the inhibitory potential of the autoantibodies in
a larger number of samples, we assayed the ability of isolated total IgG
to inhibit proteolysis of FRETS-VWF73 by the ADAMTS13 N-terminal
domains, MDTCS. Total IgG from 43 patients (29 ﬁrst presentation and
14 relapse samples) was isolated and titrated into FRETS-VWF73 activ-
ity assays to estimate the IgG concentration at which 50% enzyme inhi-
bition was achieved (IC50) (Fig. 4A–G).
IgG from 10 patients assigned to the anti-N-terminal alone group
(termed Group I) dose-dependently inhibited 125 pM MDTCS (medianusing VWF115 (top) and VWF106 (bottom) in the presence and absence of isolated IgG
within 60 min. 17 μM normal human IgG (NH IgG) did not inhibit this reaction, whereas
ng isolated total IgG (17 μM) from TTP patient samples #16, #81 (remission sample) and
f VWF106, which lacks 9 residues that are critical to ADAMTS13 spacer domain binding,
, VWF106 was only partially proteolysed by ADAMTS13 after 120 min (−IgG). Cleavage
AMTS13. Reactions containing isolated total IgG (29 μM) from TTP patient samples #16,
Fig. 4. Analysis of the inhibitory potential of total IgG isolated from acquired TTP patients. A) and B) 125 pMMDTCS was incubated with increasing concentrations of IgG isolated from
either normal or TTP patient plasmas in the absence (solid lines) and presence of preincubation with 10 nM MDTC (dotted lines). A) Normal IgG had no effect on MDTCS activity, and
addition of MDTC did not affect the activity detected. Three examples of TTP patients with anti-N-terminal alone antibodies are shown±MDTC. All samples were inhibitory and this in-
hibition was not inﬂuenced by MDTC. B) as in A, except examples of IgG isolated from patients with both anti-N- and C-terminal antibodies are shown. Note the different x-axis scale
highlighting that these IgG preparations are not as inhibitory. IgG from patients #51, #55 and #86 had no inhibitory effect uponMDTCS activity. C) Graph depicting the IgG concentration
atwhich 50% enzyme inhibitionwas achieved (IC50) for each patient testedwith antibodieswith different domain speciﬁcities. Patients are separated in ﬁve groups (Groups I–V) based on
their domain speciﬁcity and the inhibitory potential of their IgG. D) Inhibition of 125 pMMDTCS by 0.7 μM total IgG isolated from Group I samples, all samples shown inhibit MDTCS ap-
preciably at this concentration. E) Inhibition of 125 pMMDTCSby1.4 μMtotal IgG isolated fromGroup II samples. Samples shown inhibitMDTCS variably at this concentration. F) Inhibition
of 125 pMMDTCSby5.6 μMtotal IgG isolated fromGroup III samples. Samples shown inhibitMDTCSby ~50% at 5.6 μMtotal IgG. G) Inhibition of 125pMMDTCSby 5.6 μMtotal IgG isolated
from Group IV samples. At 5.6 μM total IgG, little or no inhibition of MDTCS was detected for these samples.
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contribution of anti-spacer domain antibodies to this inhibition,
in parallel, varying concentrations of total IgG were preincubated
with an 80-fold molar excess (10 nM) of puriﬁed MDTC (Fig. 4A).
At this concentration, this puriﬁed preparation of MDTC had no ef-
fect upon activity detected using normal IgG. For all 10 patient IgG
samples, preincubation with MDTC failed to detectably alter the
IC50 (Fig. 4A), further suggesting that anti-spacer domain antibodies
are the primary inhibitory antibodies.
As expected, IgG isolated from the 3 patients with only anti-C-
terminal domain antibodies (termed Group V, Fig. 4C) failed to inhibit
the activity of MDTCS even at the highest concentration tested (5.6 μM).IgG was isolated from 30 TTP patient episode samples contain-
ing both anti-N- and anti-C-terminal antibodies. 12/30 (40%) pa-
tient samples (termed Group IV), exhibited no, or minimal
inhibition of MDTCS using 5.6 μM total IgG (Fig. 4C and G). The re-
maining 18/30 (60%) patient samples with both anti-N- and anti-C-
terminal antibodies were inhibitory. However, the median IC50
(3.3 μM; range 0.2–5.6 μM) was appreciably higher than for the
samples containing only anti-N-terminal antibodies (p b 0.05).
These patients could be separated into two groups: those with an
inhibitory proﬁle similar to Group I (Group II, n = 9) (Fig. 4C and
E), and those with modest inhibitory potential (Group III, n = 9)
(Fig. 4C and F). In 9/9 Group II samples, MDTC failed to alter the
948 M.R. Thomas et al. / EBioMedicine 2 (2015) 942–952estimated IC50, again, strongly suggesting that the inhibitory anti-
bodies in these samples are those that recognise the spacer
domain.3.5. ADAMTS13 Antigen Levels
The inhibition assays suggested that the anti-ADAMTS13 autoanti-
bodies from patients in Groups IV (n = 12) and V (n = 3) (and poten-
tially also those from Group III, n = 9) may be unlikely to cause severe
functional deﬁciency of ADAMTS13 through inhibition alone, due to
their limited inhibitory capacity. We therefore hypothesised that the
loss in ADAMTS13 activity at TTP presentation in these patients may
be due to antibody-mediated depletion of ADAMTS13 antigen.
In 91 TTP presentation samples (one sample was lost to analysis due
to insufﬁcient sample size), ADAMTS13 concentrations were signiﬁ-
cantly lower [median 58 ng/ml (6% normal); range 0–450 ng/ml (0%–
47%)] than in 67 normal volunteers [median 951 ng/ml (range 515–
1829 ng/ml) p b 0.0001] (Fig. 5A). Indeed, 84/91 (92%) patients had an-
tigen levels b25%.
At ﬁrst presentation, patients with anti-N-terminal antibodies alone
(n = 23) had a median ADAMTS13 concentration of 81 ng/ml (8.5%);
range 13–331 ng/ml (Fig. 5B). Patients' samples with no detectable in-
hibitory antibodies (n = 9) had a signiﬁcantly lower ADAMTS13 con-
centration [median 2 ng/ml (0.2%); 0–141 ng/ml; p = 0.005]. Patients
with both anti-N- and C-terminal antibodies with inhibitory functionFig. 5. ADAMTS13 plasma antigen levels in acquired TTP patients. A) Plasma ADAMTS13 antige
healthy controls and 91 acquired TTP patient samples at presentation. To ensure that redu
ADAMTS13 levels were measured in pooled normal plasma (PNP) that was preincubated in t
not appreciably inﬂuence the ELISA. B) Plasma ADAMTS13 antigen levels at ﬁrst presentation in
bodies, and patients with apparently non-inhibitory antibodies (Group IV patients from Fig. 4).
vived their ﬁrst episode or died. In A–C, individual concentrations are shown, the median is reshowed a trend to lower ADAMTS13 antigen levels, compared to those
with anti-N-terminal alone [median 30 ng/ml (3.2%); range 0–
356 ng/ml; p = 0.08] (Fig. 5B). However, the median ADAMTS13 anti-
gen levels in both were signiﬁcantly higher than in episodes in which
no inhibitory antibodies were detected (p b 0.05). The same pattern
was observed examining the ADAMTS13 antigen levels in patients
assigned to Groups I–IV (Supplementary Fig. 3) — Group V patients
were not included as these were not ﬁrst presentation samples.
Interestingly, median ADAMTS13 antigen levels were signiﬁcantly
lower at presentation in patients that died during their ﬁrst episode
[12 ng/ml (1.3% normal); range 0–165)] than in survivors [57 ng/ml
(6% normal); (0–356); p b 0.05] (Fig. 5C).Moreover, ADAMTS13 antigen
levels in the lowest quartile (b13.5 ng/ml, b1.4% normal) were asso-
ciated with increased mortality (OR 5.4; 95% CI 1.5–19.3; p= 0.008),
and this remained statistically signiﬁcant whenmultivariate analysis
was performed taking age and sex as co-variates (OR 5.7; 95% CI 1.5–
21.8; p = 0.01). These results suggest that autoantibody-mediated
ADAMTS13 clearance is a major pathogenic mechanism and deter-
minant of disease severity.3.6. Longitudinal Analysis of TTP Patients
Four different patterns of clinical response to therapy were identi-
ﬁed in 26 patients surviving their index episode of TTP and for whom
longitudinal/follow-up samples were available.n levels (left axis, ng/ml; right axis % normal levels) weremeasured by ELISA in 67 normal
ced ADAMTS13 levels were not attributable to epitope masking by the autoantibodies,
he presence of IgG isolated from 14 different TTP patient episodes. Patient antibodies did
acquired TTP patients separated into anti-N-terminal alone, anti-N- and C-terminal anti-
C) Plasma ADAMTS13 antigen levels in acquired TTP patients at ﬁrst presentation that sur-
presented by a horizontal line. Statistical comparisons made are marked.
949M.R. Thomas et al. / EBioMedicine 2 (2015) 942–9521) No relapse (n = 6) All patients received standard PEX and steroid
therapy in conjunction with rituximab. Median
follow-up was 3.3 years (range 1–6.3 years) —Supplementary Table 1. Total anti-ADAMTS13
IgG titre fell following therapy with PEX, ste-
roids and rituximab (Scully et al., 2007).
There were two cases with solely anti-N-
terminal antibodies at presentation that dis-
appeared with time (one example is given in
Fig. 6A). Four patients with both anti-N and
C-terminal antibodies at presentation all cleared
the anti-C-terminal antibodies prior to anti-N-
terminal antibodies.
At one month, two patients had normal
ADAMTS13 activity, but low titre autoanti-
bodies (19% and 22%) suggesting that these au-
toantibodies were not pathogenic. Anti-
ADAMTS13 antibodies took 3 to 12 months to
clear, which coincided with the recovery of
ADAMTS13 antigen to normal levels.
2) Relapse (n = 16) The median time to either clinical relapse or to
elective rituximab given in response to a severe
drop in ADAMTS13 activity during follow-up
was 31 months (4–52 months) (Table 2). 13/16
patients had received rituximab during their ini-
tial treatment. 9/16 patients exhibited altered
domain speciﬁcity proﬁle at relapse. The most
frequent pattern (5/9 patients) was the loss of
anti-C-terminal reactivity, but reappearance of
anti-N-terminal antibodies at relapse (Fig. 6B).
3/9 patients had anti-N-terminal and high titre
anti-TSR2–8 antibodies at initial presentation,
but at relapse no longer had detectable anti-
TSR2–8 antibodies (although still had anti-C
terminal antibodies, suggesting development of
anti-CUB antibodies). 1/9 patients developed
novel anti-C-terminal antibodies at relapse, in
addition to the reappearance of anti-N-terminal
antibodies (episode #14 Fig. 6C).
3) Low ADAMTS13 activity during clinical remission There is a rare
group of patients that respond clinically to rituxi-
mab, but have persistent low plasma ADAMTS13
activity and anti-ADAMTS13 antibodies. These
patients are susceptible to multiple relapses. The
domain speciﬁcity of anti-ADAMTS13 antibodies
in two such patients revealed the persisting inhib-
itory IgG was directed against the N-terminal
domains of ADAMTS13 (Fig. 6D). ADAMTS13
antigen levels varied between 20 and 60% in
the remission samples, but plasma ADAMTS13
activity was persistently b10%, indicating the in-
hibitory nature of the persisting anti-ADAMTS13
antibodies.4) Non-pathogenic IgG in remission Two patients achieved sustained
remission (follow-up 5.1 years and 6.3 years)
after standard therapy and up-front rituximab.Fig. 6. Longitudinal analysis of acquired TTP patients. A–E) Longitudinal analysis of ﬁve ac-
quired TTP patients following a ﬁrst initial presentation. ADAMTS13 activity (blue), anti-
gen (green), anti-ADAMTS13 IgG titre (red) are shown as % normal (left axis). Platelet
counts are also shown (black, right axis). TTP episodenumber (e.g. # 32) refers to episodes
denoted in Fig. 1. Points at which rituximab (Rtx) was given are highlighted by purple ar-
rows. ADAMTS13 domain speciﬁcity results at different time points are marked in orange.
A) represents a patient that did not relapse after their ﬁrst episode. B) and C) are patients
that relapsed and whose anti-ADAMTS13 domain speciﬁcity had changed at relapse.
D) represents a patient that entered clinical remission, but had persistent low ADAMTS13
activity and inhibitory IgG and relapsed repeatedly. E) represents a patient that responded
well to rituximab and entered remission. Despite persistent anti-ADAMTS13 antibodies,
ADAMTS13 antigen and activity normalised.
Table 2
Longitudinal analysis of domain speciﬁcity of anti-ADAMTS13 IgG titre, ADAMTS13 antigen and activity in relapsing acquired TTP patients (n = 16).
TTP episode number refers to episodes denoted in Fig. 1.
First Presentation Relapse
TTP episode AutoAb speciﬁcity Act (%) Total IgG Ag (%) TTP episode AutoAb speciﬁcity Act (%) Total IgG Ag (%) Relapse/Elect Rtx TTR (mo)
#72a N & CUB b5 40 26 #19 N 5 12 47 Relapse 6
#65 N & CUB b5 84 6 – N b5 20 14 ER 34
#61 N & 2–8 b5 99 2 #29 N b5 26 10 Relapse 21
#46 N & 2–8 b5 25 3 #27 N b5 34 6 Relapse 27
#42 N & 2–8 b5 30 4 – N 15 18 0 ER 52
#55a N & 2–8 6 68 0 #92 N & CUB b5 68 1 Relapse 34
#56a N & 2–8 b5 126 n.d. #87 N & CUB b5 13 2 Relapse 36
#48 N & 2–8 b5 92 6 #64 N & CUB 27b 9 40 Relapse 4
#14 N b5 40 9 – N & CUB b5 39 15 ER 50
#23 N b5 23 7 #13 N b5 53 13 Relapse 17
#22 N b5 62 24 – N 11 13 44 ER 42
#34 N b5 23 23 – N b5 9 88 ER 31
#49 N & 2–8 b5 18 17 #44 N & 2–8 b5 23 3 Relapse 30
#62 N & 2–8 b5 34 22 #58 N & 2–8 b5 n.d. 7 Relapse 46
#86 N & CUB b5 51 10 #90 N & CUB b5 84 10 Relapse 5
#84 N & CUB b5 44 2 #80 N & CUB b5 48 2 Relapse 6
N= anti-N-terminal Abs, CUB = anti-CUB, 2–8 = anti-TSP2–8 Abs. Relapse = clinical relapse, Elect Rtx = acute drop in ADAMTS13 activity, prompting elective rituximab therapy. –=
elective rituximab, patient episodes are not presented in Figs. 1 and Supplementary Fig. 1. TTR = time to relapse (months).
a No rituximab at initial presentation. n.d. = not determined (insufﬁcient sample).
b Post PEX sample.
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at, normal levels within 1–2 months, but both
cases had persistent detectable medium-high
titre anti-ADAMTS13 IgG (25–100%) in clinical
remission. ADAMTS13 antigen levels in remis-
sion were normal, suggesting that their anti-
ADAMTS13 IgG did not promote clearance.
The persisting non-inhibitory IgG was directed
predominantly against the TSP2–8 domains
(Fig. 6E).4. Discussion
To date, this is the largest cohort in which the domain speciﬁcity of
anti-ADAMTS13 IgG at presentation has been analysed (Zheng et al.,
2010; Pos et al., 2011), and the ﬁrst to report longitudinally through
therapy, remission and relapse. The accompanying clinical and outcome
data enabled the clinical signiﬁcance of different antibody patterns to be
explored. Unlike previous studies, our competition ELISA enables esti-
mation of the proportion of anti-ADAMTS13 antibodies recognising
theN-terminal domains (Fig. 2B), rather thanmerely assessingwhether
a domain fragment-speciﬁc antibody is present/absent. Our results at
presentation broadly support ﬁndings from other studies, with 97%
of patient samples having antibodies against the MDTCS domains
(Klaus et al., 2004; Zheng et al., 2010; Pos et al., 2011). 41% of presen-
tation samples had antibodies that only recognise these N-terminal
domains. The remaining 59% of patient samples had antibodies
against C-terminal domains (28% TSP2–8 and 31% CUB1/2). In contrast
to previous studies, we found no evidence of antibodies recognising
either MD or MDTC (Klaus et al., 2004; Zheng et al., 2010).
Domain speciﬁcity of anti-ADAMTS13 antibodies at presentation
had no prognostic implication for disease severity in terms of mortality,
likelihood of a neurological/cardiac presentation, or number of PEX to
remission, suggesting that domain speciﬁcity of anti-ADAMTS13 IgG is
unlikely a major determinant of their pathogenicity. A previous study
found the presence of IgG antibodies against TSP2–8 and/or CUBwas in-
versely correlated with patient platelet counts on admission (Zheng
et al., 2010). However in our cohort, there was no difference in median
platelet count between patients with antibodies directed against the C-
terminal domains and those with solely anti-N-terminal antibodies,
once the potential confounding factor of ﬁrst versus relapsed presenta-
tion was removed. In keeping with two previous studies, we found noassociation between autoantibody/inhibitor titre and domain speciﬁcity
(Klaus et al., 2004; Zheng et al., 2010).
Analysis of longitudinal samples revealed that patients that relapsed
may have an altered domain speciﬁcity proﬁle from those at ﬁrst pre-
sentation (Fig. 6B–C). Whilst this may, in part, be explained by the fail-
ure of rituximab to eradicate all the clones of autoimmune B cells
responsible for the anti-ADAMTS13 immune response, the epitope
spreading seen in one patient (Fig. 6C) suggests a further development
of the autoimmune response in some patients, rather than simple re-
emergence of the clones responsible for the initial anti-ADAMTS13 im-
mune response. It may be that the autoimmune response to ADAMTS13
can be reconstituted from escaped CD20 positive B cells or long lived
memory cells (CD20 positive or negative) hiding in secondary lymphoid
organs: indeed the spleen has been shown to harbour ADAMTS-13 spe-
ciﬁc memory B cells following acute acquired TTP (Schaller et al., 2014).
Our results are the ﬁrst to formally demonstrate the critical role of
anti-spacer antibodies in mediating ADAMTS13 inhibition (Figs. 3, 4A–
B). We detected no antibodies other than those directed against the
spacer domain that were capable of inhibiting MDTCS function. This
suggests that, even if antibodies that recognise MDTC are present,
their inhibitory contribution relative to those targeting the spacer do-
main is not signiﬁcant. The spacer domain has long been suspected as
the primary antigenic target for inhibitory antibodies, corroborated by
mutagenesis studies (Jian et al., 2012), and also a recent analysis of
monoclonal antibodies derived from two acquired TTP patients
(Schaller et al., 2014). However, no other study has demonstrated in
this many patients that inhibitory antibodies are limited to those that
recognise the spacer domain. Despite their high frequency, anti-spacer
domain antibodies are not a prerequisite for the development of TTP,
as 3/92 patients at presentation had no evidence of anti-MDTCS anti-
bodies and yet presented with severe ADAMTS13 deﬁciency.
Although anti-spacer domain IgG appears to be themajor inhibitory
antibody species in TTP, ADAMTS13 inhibition is not the exclusive
pathogenic mechanism responsible for severe ADAMTS13 deﬁciency
in TTP. We identiﬁed 15/43 TTP patients (Groups IV and V) with anti-
ADAMTS13 IgG with little or no inhibitory function, suggesting that
the inhibitory potency of autoantibodies in many TTP patients may,
by itself, be insufﬁcient to cause the severe ADAMTS13 deﬁciency
(i.e. b 10% plasma activity). In these assays, we used 0.125 nM
ADAMTS13, which is 1/40th of the plasma ADAMTS13 concentration.
Based on the normal plasma IgG concentration of 80 μM, thismight sug-
gest that in those patients with and IC50 values N2 μM (i.e. 1/40th
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bodies would be insufﬁcient to cause severe deﬁciency in the absence
of any other pathogenicmechanism. This, in turn, implies that in poten-
tially 32/43 of the patient samples from this cohort, inhibition cannot
account for the deﬁciency state, and that only in 11/43 patient samples
might the inhibitory actions of the autoantibodies be of sufﬁcient poten-
cy to appreciably contribute to ADAMTS13 deﬁciency.
ADAMTS13 antigen was signiﬁcantly reduced (median 6% normal)
in TTP patient plasma samples, with 92% of samples having b25% nor-
mal ADAMTS13 antigen levels (Fig. 5). Antibody-mediated clearance
of ADAMTS13 antigen is likely themajor cause of loss of protease activ-
ity in acquired TTP. Low ADAMTS13 antigen levels in smaller groups of
acquired TTP patients have been previously reported (Feys et al., 2006;
Rieger et al., 2006), but despite this far greater attention has beenplaced
on the contribution of inhibitory antibodies. One group investigated the
relationship of ADAMTS13 antigen levels to anti-ADAMTS13 IgG and in-
hibitor titre, and concluded that antigen levels were lower in idiopathic
TTP patients with inhibitory autoantibodies than those with non-
inhibitory IgG or no IgG/inhibitor (Shelat et al., 2006). However, this
ﬁnding was signiﬁcantly limited by the inclusion of patients with only
moderately reduced/normal ADAMTS13 activity or no autoantibody in
their cohort.
Crucially, ADAMTS13 antigen levels at presentation have prognostic
signiﬁcance. ADAMTS13 antigen levels were lower in presentation
samples of patients who died (median 1.0% vs. 5.5%). This ﬁnding is in
keeping with a smaller study of 4 patients by Yang et al. (2011). Indeed
ADAMTS13 antigen levels in the lowest quartile at ﬁrst presentation in-
creased the likelihood of mortality by 5.7-fold.
Patient samples without detectable inhibitory antibodies had the
lowest ADAMTS13 antigen levels (Fig. 5B), suggesting that the primary
pathogenic mechanism of anti-C-terminal antibodies is through in-
creased ADAMTS13 clearance. It remains possible that some anti-C-
terminal antibodies may also compromise ADAMTS13 function. For ex-
ample, we identiﬁed two patients at ﬁrst presentationwithout evidence
of inhibitory antibodies against MDTCS, but with antigen levels N10%
(Fig. 5B). These two individuals may thus harbour autoantibodies that
recognise the C-terminal tail, which may be capable of compromising
the function of full-length ADAMTS13.
Importantly, whilst anti-spacer domain autoantibodies have the po-
tential to be inhibitory, they also promote ADAMTS13 clearance, as
ADAMTS13 antigen levels were also severely reduced in patients with
only anti-N-terminal antibodies. However, not all anti-ADAMTS13 anti-
bodies promote clearance, as anti-ADAMTS IgG titre did not correlate
with ADAMTS13 antigen. This was further exempliﬁed by two patients
that entered clinical remission with normalisation of ADAMTS13 activ-
ity and antigen levels (Fig. 6E) but persistent high-titre antibodies that
recognised ADAMTS13.
Given the apparent importance of antibody-mediated clearance
of ADAMTS13 as a signiﬁcant pathogenic mechanism underlying
ADAMTS13 deﬁciency in acquired TTP, characterisation of the under-
lying mechanism(s) is now necessary. ADAMTS13 antigen/antibody
immune complexes (IC) have been described in acute TTP and during
remission (Ferrari et al., 2012, 2014; Lotta et al., 2014), and are likely
to play an important role. Naturally, detection and assessment of the
importance of ICs at TTP presentation is potentially challenging if the
ADAMTS13 antigen levels are already very low. The clearance of IgG-
containing IC is known to occur primarily in the liver, both through both
Fc receptor-dependent and independent mechanisms (Vugmeyster
et al., 2012; Schifferli and Taylor, 1989; Emlen et al., 1992; Johansson
et al., 2002; Kosugi et al., 1992). Complement also plays an important
role in the elimination of immune complexes, with C3b binding keeping
IC soluble (Schifferli and Taylor, 1989). Erythrocytes bind these
opsonised immune complexes in the circulation via C3b receptors,
and deliver them to tissue macrophages for elimination (Emlen et al.,
1992). The spleen has also been implicated in the clearance of ICs in
some studies (Johansson et al., 2002), and the size and type of immunecomplexes may inﬂuence the relative contribution of different clear-
ance mechanisms (Vugmeyster et al., 2012).
Insight into how antibodies alter the kinetics of clearance of
ADAMTS13 perhaps has more profound and immediate implications.
ADAMTS13 has a relatively long active plasma half-life of 2–3 days
(Furlan et al., 1999), suggesting its baseline rate of clearance is normally
relatively slow. As over 70% of the TTP patients' samples that we
analysed had no or low inhibitory potential, this could suggest that pro-
vision of recombinant ADAMTS13 to acquired TTP patients may not re-
sult in rapid inhibition of the enzyme in an appreciable proportion of
patients. If the autoantibodies in these patients are non-inhibitory and
their enhancement of clearance is not very rapid (which seems unlike-
ly), this may allow recombinant ADAMTS13 a window of therapeutic
beneﬁt in these patients, and potentially reduce the number of PEX re-
quired to achieve remission.
This study has improved our understanding of the immunological
basis of acquired TTP, which accounts for the vast majority of TTP
cases. It has for the ﬁrst time investigated the contribution of antibodies
against different ADAMTS13 domains to the inhibitory potential in plas-
ma, and revealed that antibodies against the spacer domain are the pri-
mary inhibitory species. However, our results implicate antibody-
mediated ADAMTS13 depletion as a signiﬁcant pathogenic mechanism
underlying severe loss of enzyme activity in acquired TTP. This has con-
siderable relevance, not only to how the diagnosis of acquired TTP is
conﬁrmed with ADAMTS13 assays, but also to prognosis and the possi-
ble beneﬁt of ADAMTS13 replacement in acute therapy for TTP. The ap-
preciable proportion of acquired TTP patients with non-inhibitory/
weakly inhibitory anti-ADAMTS13 IgG, may imply that recombinant
ADAMTS13 could have therapeutic potential as an adjunct to standard
therapy, without the need for provision of very high ADAMTS13 con-
centrations to overcome antibody-mediated inhibition. It is now imper-
ative to understand the mechanisms and kinetics of clearance to
ascertain whether there is a therapeutic window for such treatment.
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